Marijuana Stocks & Public Companies

Marijuana Business Stock Ticker

Chris Walsh  | April 30, 2015
More than 100 marijuana stocks are currently listed on NASDAQ. Click to see our chart of the most relevant ones.

Helix TCS becomes largest single shareholder in MJ software firm

John Schroyer  | November 7, 2016

Colorado-based Helix TCS, which has been expanding its holdings in the marijuana trade, announced Monday it has become the largest shareholder in Florida-based BioTrackTHC, a longtime manufacturer and supplier of seed-to-sale cannabis tracking software.

Specific terms of the deal were not disclosed.

Helix and its capital partner, Rose Capital Advisors of Miami Beach, agreed to …

Zacks Investment: 4 best stocks to cash in on cannabis ‘green rush’

Bart Schaneman  | November 4, 2016

The decades-old Zacks Investment Research is recommending four “cannabis-related” companies – including some household names – for stock investors wanting to cash in on the so-called marijuana “green rush.”

The stock research firm, founded in 1977, projects that Tuesday’s election will yield yes votes in several states where marijuana legalization initiatives are on the …

Week in Review: Detroit crackdown, NYSE listing bid & LSU proposes big bucks on MMJ

Bart Schaneman  | October 21, 2016

By Bart Schaneman, Omar Sacirbey and John Schroyer

Detroit cracks down on dispensaries, a cannabis real estate investment trust eyes a Big Board listing, and Louisiana State University proposes spending millions on medical marijuana cultivation.

Here’s a closer look at some notable developments in the marijuana industry over the past week.

Another Canadian MMJ cultivator plans to go public

Bart Schaneman  | October 14, 2016

Canadian medical cannabis producer Emblem is set to go public next month on the TSX Venture Exchange, the electronic exchange owned by the parent of the Toronto Stock Exchange.

The Ontario company is the latest federally licensed medical marijuana cultivator to list its shares on an exchange, thanks to Canada’s legalized MMJ industry.

Emblem …

Week in Review: San Diego crackdown, WA eyes organic marijuana & Britain says yes to CBD

John Schroyer  | October 14, 2016

By Bart Schaneman and John Schroyer

San Diego targets illegal dispensaries while educating consumers about legit operations, Washington State has an eye toward organic certification, and Britain gives CBD the medicinal green light.

Here’s a closer look at some notable developments in the marijuana industry over the past week.

Cultivator Aurora Cannabis raises CA$25 million

Omar Sacirbey  | October 11, 2016

Alberta, Canada-based medical marijuana cultivator Aurora Cannabis announced Tuesday that it plans to raise 25 million Canadian dollars ($19 million) in a private placement of convertible debentures.

The debt instruments mature in two years and can be converted into shares priced at CA$2.

Under the terms of the private placement, Aurora said in …

MassRoots pays off March debt of nearly $1M

John Schroyer  | October 7, 2016

MassRoots, the publicly traded cannabis-centric social media site, said Friday it has repaid its creditors after disclosing last month it had missed nearly $1 million in payments that were due to holders of its convertible notes.

“We’re excited to have this debt fully repaid and behind us. We expect MassRoots will be cash-flow …

Week in Review: MassRoots’ woes, GW Pharma’s good news & pro-legalization polls

Omar Sacirbey  | September 30, 2016

By Omar Sacirbey and John Schroyer

MassRoots lands in financial hot water, GW Pharmaceuticals takes a step closer to winning U.S. approval for its marijuana-based drug, and a political veteran urges caution heading into the elections.

Here’s a closer look at some notable developments in the marijuana industry over the past week.

GW Pharma’s latest clinical trial successful, stock soars

John Schroyer  | September 27, 2016

British cannabis company GW Pharmaceuticals has conducted a successful clinical trial in which it treated epileptic children with one of its marijuana-based drugs, triggering a surge in the company’s stock price.

According to Reuters, tested doses of GW Pharmaceutical’s drug Epidiolex “were found to have induced a statistically significant improvement in reducing seizures” …